pre-existing heart disease and advanced age. 25 Moreover, there seems to be a gender-related predisposition. Although experimental data point towards better resistance from women regarding cardiotoxicity with involvement of mitochondria and less oxidative stress, very few studies have been conducted in humans, although female patients in clinical studies appear to be more susceptible to doxorubicininduced cardiotoxicity. 2, 27, 28 This apparent paradox may be explained because both age and menopausal status seem to be the two most important determinants of the sex-specific differences observed in the clinical setting, with higher susceptibility in prepuberal girls and postmenopausal women. Studies in young children receiving anticancer drugs for haematological malignancies suggest that prepuberal girls are more susceptible to develop early or late cardiac toxicity than boys of the same age. 27, 29 These data are consistent with the absence of female hormones at this age. Unfortunately, no survey has been conducted to specifically assess sex differences in the occurrence of ANT cardiotoxicity in adults. ANTs are characterised by a marked susceptibility to be rapidly reduced to unstable metabolites, such as doxorubicin-semiquinone, which generate hydrogen peroxide and superoxide by reacting with oxygen. ROS are also produced thanks to the ability of these drugs to chelate intracellular free iron, creating iron-doxorubicin complexes that react with oxygen ( Figure 1 ). Furthermore, ANTs can directly interfere with the activity of major iron-transporting and iron-binding proteins, such as ABCB8, a mitochondrial iron exporter, promoting mitochondrial iron accumulation and ROS production. It has also been observed that hearts from patients with doxorubicin-related heart dysfunction have significantly higher mitochondrial iron levels than in patients with other types of cardiomyopathies or normal cardiac function. 30 Research led by Edward Yeh has shown that the production of ROS could also be secondary to the interaction of ANTs with the beta isozyme of topoisomerase 2 (Top2), the only isoform expressed by adult mammalian cardiomyocytes. 31 While the interaction of the drug with Top2-alpha -overexpressed in proliferating cancerous cells but not in quiescent tissues -generates a ternary Top2-doxorubicin-DNA cleavage complex that in turn triggers the death of tumour cells, the Top2-beta-doxorubicin-DNA complex induces DNA double strand breaks, ultimately promoting cardiomyocyte death. 31 The ensuing DNA break induces the activation of p53, an enzyme that activates the proteins responsible for the DNA repair process, but can also repress genes involved in mitochondrial biogenesis, such as PPARGC1, oxidative phosphorylation, ultimately leading to defective organelle biogenesis and metabolic failure. 31 An abnormal accumulation of mitochondria damaged by doxorubicin in the myocardium has also been reported, promoting the production of ROS and the death of cardiomyocytes. This accumulation would seem to be caused by the activation of p53, which is able to inhibit the normal recycling of dysfunctional mitochondria via autophagy. 9 ANTs are also involved in the activation of the mitogen-activated protein kinase (MAPK) cascade through reactive oxygen species and Ca2+. In particular, it is worth mentioning the role of p38 MAPK in the induction of cardiomyocyte death. 32 It has been demonstrated that before any clinical sign of LV dysfunction in ANT cardiotoxicity, there is a reduction in the phosphocreatine:adenosine triphosphate ratio, suggesting the presence of alterations in myocardial energetics. 33 In this study, the authors also demonstrated that ANTs can affect the normal functioning of creatine kinase (CK) by oxidising its sulfhydryl groups. More studies on this pathway are needed to identify novel cardioprotective therapeutic approaches. The possible protective role of CK in heart diseases is supported by improved cardiac function in murine hearts overexpressing myofibrillar CK and subjected to pressure overload, compared with non-transgenic mice. 34 Moreover, CK overexpression seems to improve cardiac function and general myocardial energetics and also the survival of mice affected by CTX induced by ANTs. 9 Reproduced with permission from Frontiers.
Several approaches have been proposed to reduce ANT CTX. Beside limiting the cumulative anthracycline doses, the interest of the scientific community has also been focusing on antioxidant drugs. 2, 3 However, none of these strategies is unanimously recommended, emphasising the need for further studies. 8 The use of dexrazoxane has been clinically evaluated in children treated with doxorubicin for acute lymphoblastic leukaemia, resulting in reduced myocardial injury, as indicated by a decreased level of serum troponin T. 15, 38 Among traditional HF drugs, beta-blockers have been shown to reduce oxidative stress and calcium overload in myocardial cells. 39, 40 Carvedilol has been shown to have a preventive role against LV dysfunction in patients treated with ANTs reducing the production of ROS, apoptosis of cardiomyocytes and mitochondrial alterations. [41] [42] [43] In some experimental models of ANT-induced cardiotoxicity, nebivolol was also able to improve LV function, increase nitric oxide (NO) levels and reduce oxidative stress. 44, 45 Nebivolol, used before ANT-based treatments, also reduced the incidence of LV dysfunction, compared with placebo. 46 The renin-angiotensin-aldosterone system also plays a key role in ANT-induced CTX. 47 In particular, in patients treated with ANTs, enalapril reduced the incidence of LV dysfunction when compared with placebo. 48 In vitro and in vivo experiments demonstrated the cardioprotective effects of angiotensin receptor blockers -candesartan can reduce in vitro ANT cardiotoxicity, while telmisartan can blunt acute LV dysfunction induced by doxorubicin when administered pre-and post-chemotherapy in rats. 49 Furthermore, telmisartan can inhibit the production of TNF-alpha and interleukin 6 and can affect the availability of NO. 50 It also seems that the co-administration of angiotensin-converting enzyme inhibitors and carvedilol can reduce cardiac damage induced by ANTs. Patients With HER2 + Breast Cancer (SAFE-HEaRt study) has been designed to evaluate whether anti-HER2 therapies can be given to women with mildly reduced heart function and optimised cardiac therapy and monitoring. 55 The mechanisms of CTX induced by ErbB2 blockers have not been fully elucidated (Figure 2 ). In the heart, neuregulin, secreted from The interactions between ANT and trastuzumab have been extensively studied. The coadministration of trastuzumab with ANTs in people with breast cancer, increased ANT toxicity in early trials and is now avoided. [61] [62] [63] In fact, it has now been shown that anti-HER-2 drugs block the protective mechanisms of HER-2, exacerbating the oxidative damage caused by ANTs. 12, 64 ErbB2 knockout mice develop dilated cardiomyopathy and show a higher prevalence of cardiomyocyte death when treated with ANT. 65 On the other hand, Belmonte et al. demonstrated that overexpression of ErbB2 in the heart reduced ROS levels, increasing the activity of glutathione peroxidase 1 and its co-activating factors such as c-Abl and Arg. 66 The same group reported a bidirectional crossregulation between ErbB2 and beta-adrenergic signalling pathways. 67 Interestingly, patients treated with trastuzumab, ANTs, or both have been shown to be exposed to reduced risk of LV dysfunction when incidentally administered with beta-blockers. 68 Recent data suggest that beta-blockers, such as bisoprolol and metoprolol are not able to fully prevent trastuzumab-induced cardiomyopathy, showing that blockade of beta-1 alone is not sufficient to protect the heart.
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While non-selective beta-blockers did not really prove beneficial in the ANT setting, these clinical and experimental findings support their use in the trastuzumab setting. 
67,71

Trastuzumab is a monoclonal antibody that binds the extracellular domain IV of human epidermal growth factor receptor 2 (HER-2). It is used to treat breast cancer patients (~30%) in whom HER-2 is overexpressed and spontaneously homodimerises or forms heterodimers with other HER receptors, especially HER-3. This ligand-independent activation of HER-2 promotes proliferation and survival of tumour cells. Trastuzumab blocks the interaction HER-2/HER-3 and downstream signalling halting the growth of tumour cells. Moreover, trastuzumab induces the antibody-dependent immune cell-mediated cytotoxicity of cancer cells (left side). In the heart, neuregulin-1 (NRG-1) triggers HER-4/HER-4 homodimerisation and HER-4/HER-2 heterodimerisation on cardiomyocytes to induce protective pathways in response to stress. Blockade of cardiac HER-2 by trastuzumab results in the disruption of NRG-1-dependent signaling and consequently in alterations of structure and functions that cause cardiomyocyte death (right side). HER = human epidermal growth factor receptor; NRG = neuregulin. Source: Varricchi et al. 2018. 9 Reproduced with permission from Frontiers. C A R D I A C FA I L U R E R E V I E W
Anti-vascular Endothelial Growth Factor Drugs
As seen above, ROS play a central role in the mechanisms of CTX induced by ANTs and by ErbB2 blockers. AMPK, which may have a role in ANT-induced cardiotoxicity, seems to be targeted also by the tyrosine kinase inhibitor sunitinib. Indeed, sunitinib is primarily known as a vascular endothelial growth factor (VEGF) inhibitor, but it is also a multiple tyrosine kinase inhibitor. Among many other kinases (>30), it can inhibit ribosomal S6 kinase, activating the intrinsic apoptotic pathway, and AMPK (usually activated by energetic stress), contributing to the reduction of adenosine triphosphate levels. 52, 72, 73 Our preliminary findings show that CK can also modulate sunitinib actions on the contractile apparatus of cardiomyocytes by regulating oxidative stress. 74, 75 Additionally, it seems that sunitinib can prolong the opening time of the mitochondrial permeability transition pore, with consequent swelling and deformation of the mitochondria in murine cardiomyocytes affected by pressure overload. 76 Conversely, studies have demonstrated that oxidative phosphorylation is not significantly affected by sunitinib and suggest that its CTX is less frequent than predicted. 77 It has been shown that sunitinib damages pericytes and can affect the microvascular circulation of the heart, rather than impair cardiomyocyte functionality directly, and a recent paper has investigated the connection between afterload and sunitinib-induced CTX. 78, 79 Using a preclinical model of engineered cardiomyocytes (first murine and then human), Truitt et al. demonstrated that sunitinib can induce cardiomyocyte death, decrease the contractile force of the heart and generate spontaneous beating at clinical doses. They also found a correlation between an increase in the afterload and the CTX induced by sunitinib. According to these findings, antihypertensive therapies may be used to reduce the effects of sunitinib. 79 Sorafenib is another tyrosine kinase inhibitor with significant CTX.
Most of the information we have on CTX induced by sunitinib and sorafenib comes from two meta-analyses including almost 7,000 patients given sunitinib and 900 patients given sorafenib. These showed that 4.1% of patients treated with sunitinib developed HF, while 1% of patients treated with sorafenib had signs of cardiac dysfunction. 80, 81 It is important to highlight that both meta-analyses only B and interferon-gamma ( Figure 3) . 18 However, immune checkpoints play a central role in the maintenance of self-tolerance. Therefore, blocking these pathways can lead to imbalances in immunologic tolerance that results in immune-related adverse events. 90 These sideeffects are common, but fortunately in most cases they are reversible and not severe. They include mostly skin manifestations, such as pruritus, rash and vitiligo in 43-45% of patients, but also liver and gastrointestinal events that may occur 6-7 weeks after treatment was initiated. Greater concern is expressed on endocrinopathies, observed in about 6-8% of patients. They are the only immune-related adverse events with a high risk of irreversible toxicity and result from immune infiltration into either the thyroid or pituitary glands, causing thyroiditis or hypophysitis, respectively. [91] [92] [93] When ICIs were introduced as cancer treatments, little attention was paid to cardiac side-effects. Then, isolated cases of fulminant myocarditis ( Figure 3) showing that these molecules can prevent autoimmunity. 100 Furthermore, absence of PD-L1, or its inhibition, can worsen the survival from myocarditis, suggesting a role for PD-1/PD-L1 and CTLA-4
A: Tumour cells escape immune surveillance by promoting checkpoint activation. Tumour cells express the immune checkpoint activator programmed cell death ligand 1 (PD-L1) and produce antigens (blue dots) that are captured by antigen-presenting cells (APCs). These cells present antigens to cytotoxic CD8+ T cells through the interaction of major histocompatibility complex (MHC) molecules and T-cell receptor (TCR). T-cell activation requires costimulatory signals mediated by the interaction between B7 and CD28. Inhibitory signals from cytotoxic T lymphocyteassociated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) checkpoints dampen T-cell response and promote tumour proliferation. B: Checkpoint inhibitors stimulate T-cell activation. Monoclonal antibodies targeting CTLA-4 (ipilimumab), PD-1 (nivolumab, pembrolizumab), and PD-L1 (atezolizumab, avelumab, durvalumab) block immune inhibitory checkpoints (CTLA-4, PD-1, and PD-L1, respectively) and restore antitumour immune response, resulting in tumour cell death via release of cytolytic molecules (e.g. tumour necrosis factor-alpha, granzyme B, interferon gamma). C: Hypothetical mechanism by which checkpoint inhibitors can promote autoimmune lymphocytic myocarditis. PD-L1 is expressed in human and murine cardiomyocytes, and its expression can increase during myocardial injury. Combination of checkpoint blockade (ipilimumab plus nivolumab) unleashes immune responses and can
in limitation of T cell-mediated autoimmune myocarditis. Interestingly, PD-1 and PD-L1 were observed to be increased in cardiomyocytes from rat hearts subjected to ischaemia-reperfusion.
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Future Perspectives
Cardio-oncology is an ever-expanding field of research. In this article we have only discussed the studies conducted on ANTs anti-HER2 drugs and anti-VEGF drugs, but several other drugs (alkylating agents, antimetabolites, proteasome inhibitors, other, tyrosine kinase inhibitors, antimicrotubule agents) can generate LV dysfunction.
17
A tight collaboration among cardiologists and oncologists is building up quickly. 102, 103 Immunotherapies have been introduced more recently, and in view of the fact that autoimmune myocarditis induced by ICIs has fulminant progression, including immunologists in this cardio-oncologic collaboration appears necessary for better management of ICI CTX. 104 At the moment, beyond ICIs, novel monoclonal antibodies targeting several immune checkpoints, and new cancer therapies, such as engineered T cells, cancer vaccines and PI3K inhibitors are being studied and developed. [105] [106] [107] [108] A thorough cardio-immuno-oncologic collaboration seems fundamental, to the assessment of potential toxicities of current and novel drugs, in clinical as well as in basic research also considering that these drugs are often combined, thus increasing their cardiotoxic potential. 99, 109 In addition, novel data point to a direct relationship between cancer and the heart. Indeed, cancer and HF share common 
